NGENF Stock Price, Chart, Stats & News

NervGen Pharma Corp., including its affiliated entities, is focused on discovering, advancing, and bringing to market pharmaceutical solutions designed to address medical conditions arising from damage to the nervous system. Their primary experimental compound, NVG-291, is currently undergoing Phase 1 clinical trials to assess its potential effectiveness for spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company also maintains a licensing partnership with Case Western Reserve University, enabling them to research, further develop, and commercialize a patented technology that shows therapeutic promise for SCI and other conditions linked to nerve damage.